India’s Aurobindo Pharma receives USFDA approval

Aurobindo Pharma Limited has received tentative approval from the US Food & Drug Administration to make and sell Venlafaxine Hydrochloride Extended-release

These capsules are indicated for the treatment of major depressive disorder (MDD) and falls under the Neurological (CNS) therapeutic category. The product has a market size of US$ 2.4 billion (in 2010) according to IMS.

The tentatively approved ANDA  is currently under litigation in the United States District Court [Wyeth LLC v. Aurobindo Pharma Limited]. The product will be launched after the litigation settlement.

Headquartered in India’s Hyderabad, Aurobindo Pharma Limited ( makes generic pharmaceuticals and active pharmaceutical ingredients.


Leave a Reply

Your email address will not be published. Required fields are marked *